The FDA has accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG for treating patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS). The agency assigned a PDUFA target action date of January 6, 2027.

Clinical Takeaway

The FDA’s acceptance of this sBLA represents a potential expansion of ANKTIVA plus BCG to treat the larger subset of BCG-unresponsive NMIBC patients with papillary-only disease. Currently, approximately 85% of the 64,000 people diagnosed with NMIBC annually in the U.S. present with papillary disease, yet no FDA-approved bladder-sparing therapy exists for this population when BCG becomes ineffective.

Drug Profile & Current Indication

ANKTIVA (nogapendekin alfa inbakicept-pmln) is an immunotherapy approved by the FDA in April 2024 for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors, when used in combination with BCG.

Rationale for Label Expansion

The FDA noted that the sBLA was based on additional scientific data ImmunityBio provided detailing the overlapping features of papillary and CIS disease. The agency will focus its review on determining whether there is adequate justification to allow extrapolation of results from patients with CIS to those with papillary-only disease.

Supporting this approach, an FDA workshop held on May 18, 2026 featured expert panelists who stated that:

  • CIS and papillary disease arise from the same cancer-inducing clone and are therefore biologically similar
  • When papillary disease alone is identified, clinicians treat patients off-label with FDA-approved therapies for CIS and papillary disease

This expert consensus aligns with the NCCN panel’s March 2026 decision to designate treatment of BCG-unresponsive NMIBC papillary disease as a Category 2A guideline for practicing urologists.

Supporting Clinical Data

The sBLA is supported by data from the QUILT 3.032 Phase 2/3 trial (Cohort B) in 80 patients with high-grade papillary-only NMIBC. Published in The Journal of Urology, the study met its primary endpoint with encouraging efficacy and bladder-preservation outcomes.

Efficacy Outcomes

  • Primary Endpoint:
    • 12-month disease-free survival (DFS): 58.2% (95% CI: 46.6-68.2%)
  • Secondary Endpoints:
    • Progression-Free Survival (PFS): 94.9% at 12 months and 82.0% at 36 months
    • Cystectomy-Free Survival: 92.2% at 12 months and 83.1% at 36 months
    • Disease-Specific Survival (DSS): 96.0% at 36 months, with median DSS not yet reached

Safety Profile

The safety data submitted in the sBLA were consistent with the safety profile of the currently approved indication. The serious adverse events of ANKTIVA combined with BCG were qualitatively consistent with those observed with BCG alone.

Key Clinical Implications

✔ Addresses significant unmet need: Patients with BCG-unresponsive papillary NMIBC currently face radical cystectomy or limited off-label treatment options

✔ Potential for bladder preservation: Over 80% of patients avoided radical cystectomy through three years of follow-up in the supporting trial

✔ Chemotherapy-free approach: ANKTIVA plus BCG represents an immunotherapy-based treatment strategy for high-grade NMIBC

✔ Aligns with clinical practice: Expert consensus supports treating papillary and CIS disease similarly based on biological overlap

Bottom Line

If approved, this label expansion would make ANKTIVA plus BCG available to patients with BCG-unresponsive NMIBC and papillary-only disease, a population with limited bladder-sparing treatment options beyond radical cystectomy. The January 6, 2027 PDUFA date will determine whether this expanded indication receives FDA approval.

Sources: